
CAC2 Childhood Cancer Community News Digest (November 13-19)
Assorted News from the Last Week: The Childhood Cancer Data Initiative (CCDI) awarded eight administrative supplements to NCI-Designated Cancer Centers to investigate how data in
Assorted News from the Last Week: The Childhood Cancer Data Initiative (CCDI) awarded eight administrative supplements to NCI-Designated Cancer Centers to investigate how data in
By CAC2 Organizational Member David Achey (Wit You Against Childhood Cancer) Childhood cancer is a challenging experience that affects everyone: the child, their family and
Assorted News from the Last Week: World Health Organization joins forces with St. Jude Children’s Research Hospital and other key countries to coordinate vital humanitarian
Assorted News from the Last Week: While new treatments for leukemia have improved outcomes for many patients, children with Down syndrome have not benefited as
Assorted News from the Last Week: The US National Childhood Cancer Registry (NCCR) is combining data from myriad sources to hasten and improve research into
Assorted News from the Last Week: Trial results confirm effectiveness of Atezolizumab against a rare sarcoma. By a 14-6 vote, the Oncologic Drugs Advisory Committee
Assorted News from the Last Week: Video distraction minimizes anesthesia for children undergoing radiotherapy. Supporting the family affected by a pediatric cancer diagnosis: siblings matter,
Assorted News from the Last Week: Opinion piece from the New York Times: It Takes a Lifetime to Survive Childhood Cancer. (with a bonus that
Assorted News from the Last Week: On September 26, 2023, the FDA approved bosutinib (Bosulif, Pfizer) for pediatric patients 1 year of age and older
Assorted News from the Last Week: U.S. Congressman Michael McCaul (R-Texas) and Childhood Cancer Caucus Co-Chairs Ami Bera (D-Calif.) and Mike Kelly (R-Pa.) introduced the